Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Tolerance Restoration In Autoimmune Diseases by selective manipulation of the CD28 costimulatory pathway

Objective

"The TRIAD, Tolerance Restoration In Autoimmune Disease, consortium provides an innovative strategy to autoimmune diseases (AID) therapy, based on antibody approach with a well established mechanism of action. The main objective is the evaluation of a selective antagonist of CD28 to prevent, treat and/or cure some AIDs in preclinical models including rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, uveitis and arteriosclerosis.

The concept is based on rather than suppressing the immune system as a whole, suppressing only the parts of the immune system responsible for the autoimmune attack, while sparing and enhancing regulatory T cells. Costimulation through the CD28/B7/CTLA-4 molecular triad controls the balance effector/regulatory functions after initial antigen exposure. An antagonist anti-CD28 represents a novel drug candidate allowing very specific immunosuppression compatible with regulatory T cells function, immune regulation and therefore tolerance induction/restoration.

The TRIAD project will start with the study of the efficacy of a new selective antagonist of CD28 in non-human primate models and the exploration of the potential efficacy of surrogate CD28 antagonist in rodent models. Then will be performed an evaluation of potential immunological toxicity of the antagonist in humanized SCID mice and non-human primate, to exclude agonist activity in vivo. Previously identified mechanisms of action (i.e. costimulation blockade and induction of Tregs) in the context of AID will be confirmed in experimental models. Formulation and preclinical toxicological studies will be run before initiating PhaseI/II trial in patients.

TRIAD capitalises on the strong experience available in Brazil and Europe in the field of immunology. It comprises 6 academic institutions and 1 SME being the coordinator of the 3-year project. International cooperation with project is ensured by the integration of a leading Brazilian research centre in the consortium."

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2011-single-stage
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-FP - Small or medium-scale focused research project

Coordinator

EFFIMUNE SAS
EU contribution
€ 1 310 262,60
Address
RUE GASTON VEIL 1
44035 NANTES
France

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (6)

My booklet 0 0